N. Makretsov

发表

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

F M Blows, E Provenzano, C Caldas, 2010, British Journal of Cancer.

Are Pathologists Biased? Effect of Blinding on Pathologist Assessment of Lymph-Vascular Invasion in Breast Cancer (Proposal for New Generation Internet-Based Randomized Controlled Trial Design)

N. Makretsov, 2014 .

Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer.

D. Huntsman, C. Gilks, M. Hayes, 2003, Human pathology.

Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression

D. Huntsman, C. Gilks, L. Prentice, 2004, Cancer Research.

Advances in Brief Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression

D. Huntsman, C. Gilks, L. Prentice, 2004 .

Thank You to Reviewers

E. McCready, C. Depp, L. Deserno, 2015, Journal of Public Health Policy.

NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis

T. Nielsen, R. deLeeuw, W. Lam, 2005, Oncogene.

Development of an evidence-based approach to external quality assurance for breast cancer hormone receptor immunohistochemistry: comparison of reference values.

C. Gilks, R. Alaghehbandan, E. Torlakovic, 2011, Archives of pathology & laboratory medicine.

Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival.

D. Huntsman, Gang Li, Changzheng Huang, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A fluorescence in situ hybridization study of ETV6‐NTRK3 fusion gene in secretory breast carcinoma

P. Sorensen, D. Horsman, D. Huntsman, 2004, Genes, chromosomes & cancer.

Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma

Michael Peacock, C Blake Gilks, David G Huntsman, 2004, Clinical Cancer Research.

Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.

Stephen Chia, David Huntsman, Anthony Magliocco, 2006, Gynecologic oncology.

Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data

Matt van de Rijn, David Huntsman, Anthony Magliocco, 2007, Modern Pathology.

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

G. Giles, G. Severi, G. Turashvili, 2010, British Journal of Cancer.

The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis

D. Huntsman, B. Gilks, K. Gelmon, 2004, Modern Pathology.

Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival

T. Nielsen, D. Huntsman, C. Gilks, 2004, Cancer Research.

Tissue microarray analysis of connexin expression and its prognostic significance in human breast cancer.

E. Yorida, C. Naus, J. Bechberger, 2007, Cancer letters.

The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis

D. Huntsman, B. Gilks, K. Gelmon, 2004, Modern Pathology.

Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival

S. Wiseman, T. Nielsen, D. Huntsman, 2005, Cancer.

Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade

D. Huntsman, C. Gilks, M. Hayes, 2007, Modern Pathology.

Now, Later of Never: Multicenter Randomized Controlled Trial Call—Is Surgery Necessary after Atypical Breast Core Biopsy Results in Mammographic Screening Settings?

N. Makretsov, 2015, International journal of surgical oncology.